MétaCan
Menu
Back to cohort
Record W4400100563 · doi:10.1136/bmjopen-2023-080143

Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis

2024· article· en· W4400100563 on OpenAlexaff
Nasir Hussain, Christopher Ma, Gideon M. Hirschfield, Martine Walmsley, Paula Hanford, Mette Vesterhus, Kris V. Kowdley, Annika Bergquist, Cyriel Y. Ponsioen, Cynthia Levy, David N. Assis, Christoph Schramm, Christopher L. Bowlus, Michael Trauner, Olalekan Lee Aiyegbusi, Vipul Jairath, Palak Trivedi

Bibliographic record

VenueBMJ Open · 2024
Typearticle
Languageen
FieldMedicine
TopicLiver Diseases and Immunity
Canadian institutionsWestern UniversityUniversity of TorontoToronto Liver CentreUniversity of Calgary
FundersNational Center for Advancing Translational SciencesWellcome Trust
KeywordsMedicineClinical trialDelphi methodStakeholderClinical endpointStakeholder engagementPrimary sclerosing cholangitisProtocol (science)MEDLINEAlternative medicineFamily medicineMedical physicsDiseasePathologyPublic relations

Abstract

fetched live from OpenAlex

BACKGROUND: Primary sclerosing cholangitis (PSC) is a progressive immune-mediated liver disease, for which no medical therapy has been shown to slow disease progression. However, the horizon for new therapies is encouraging, with several innovative clinical trials in progress. Despite these advancements, there is considerable heterogeneity in the outcomes studied, with lack of consensus as to what outcomes to measure, when to measure and how to measure. Furthermore, there has been a paradigm shift in PSC treatment targets over recent years, moving from biochemistry-based endpoints to histological assessment of liver fibrosis, imaging-based biomarkers and patient-reported outcome measures. The abundance of new interventional trials and evolving endpoints pose opportunities for all stakeholders involved in evaluating novel therapies. To this effect, there is a need to harmonise measures used in clinical trials through the development of a core outcome set (COS). METHODS AND ANALYSIS: Synthesis of a PSC-specific COS will be conducted in four stages. Initially, a systematic literature review will be performed to identify outcomes previously used in PSC trials, followed by semistructured qualitative interviews conducted with key stakeholders. The latter may include patients, clinicians, researchers, pharmaceutical industry representatives and healthcare payers and regulatory agencies, to identify additional outcomes of importance. Using the outcomes generated from the literature review and stakeholder interviews, an international two-round Delphi survey will be conducted to prioritise outcomes for inclusion in the COS. Finally, a consensus meeting will be convened to ratify the COS and disseminate findings for application in future PSC trials. ETHICS AND DISSEMINATION: Ethical approval has been granted by the East Midlands-Leicester Central Research Ethics Committee (Ref: 24/EM/0126) for this study. The COS from this study will be widely disseminated including publication in peer-reviewed journals, international conferences, promotion through patient-support groups and made available on the Core Outcomes Measurement in Effectiveness Trials (COMET) database. TRIAL REGISTRATION NUMBER: 1239.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.313
metaresearch head score (Gemma)0.317
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesMetaresearch
DomainCandidate signal: Methods · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.687
Threshold uncertainty score0.847

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.3130.317
Meta-epidemiology (narrow)0.0050.005
Meta-epidemiology (broad)0.0090.013
Bibliometrics0.0120.012
Science and technology studies0.0070.006
Scholarly communication0.0120.009
Open science0.0070.009
Research integrity0.0130.016
Insufficient payload (model declined to judge)0.0930.030

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.833
GPT teacher head0.661
Teacher spread0.173 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; the direct Gemma label and the distilled Codex classifier agree on what is shown here.

Study designNot applicable
DomainMethods
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueBMJ OpenSame topicLiver Diseases and ImmunityFrench-language works237,207